Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

These may range from a mildly symptomatic clinical picture to one characterised by chest pain, heart failure and cardiogenic shock necessitating mechanical circulatory support, as well as ...

Windtree Therapeutics (WINT) announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a ...

Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that ...

Danvers: Johnson & Johnson MedTech, has announced that the U.S. Food and Drug Administration (FDA) has expanded the ...

The company has collaborated with ACTION to gather real-world data supporting the on-label use of heart pumps.

The FDA has opened up the use of Johnson & Johnson’s miniaturized heart pumps to certain pediatric patients, including those ...

WARRINGTON, PA — Windtree Therapeutics, Inc. has announced a new patent application for istaroxime derivatives, aimed at preventing or reducing the risk of acute myocardial arrhythmia. The filing ...

Johnson & Johnson today announced the FDA has expanded its approval of Impella heart pumps to treat specific pediatric ...

Physicians have a new treatment option for many of the sickest pediatric patients with heart failure and cardiogenic shock. Johnson & Johnson MedTech, the global leader in heart recovery, announced ...

In the absence of full guidelines, this expert consensus decision pathway gives practical advice for clinicians.

Second Heart Assist announced today that it completed the third in a planned series of studies for its mechanical circulatory ...